Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection

Okwen, Mbah P; Reid, Savanna; Njei, Basile; Mbuagbaw, Lawrence

doi:10.1002/14651858.cd009886.pub2

Cited by 6 publications

(6 citation statements)

References 49 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A trial of immunogenicity and safety of 2vHPV in HIV-infected females is underway [88]. It may be useful to treat the HIV infection and partially reconstitute the immune system prior to vaccination, and once vaccinated, maintenance of ART may sustain protection against HPV [89]. It would be useful to know whether HPV vaccination by either or both vaccines reduces cancer risk in HIV-infected populations and whether the degree of immunosuppression influences protection.…”

Section: Immunosuppressed Populationsmentioning

confidence: 99%

“…This is a particularly relevant question in some low-resource settings where there may be less access to antiretroviral therapy (ART). It may be useful to treat the HIV infection and partially reconstitute the immune system prior to vaccination, and once vaccinated, maintenance of ART may sustain protection against HPV [89].…”

Section: First Generation Of Hpv Vaccines: Bi- and Quadrivalentmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic HPV vaccination: past, present, and future

Castle

Maza²

2015

Epidemiol. Infect.

156

114

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most common cancer and cause of cancer-related death in females worldwide. HPV also causes anal, vaginal, vulvar, penile, and oropharyngeal cancer. Prophylactic HPV vaccines based on recombinantly expressed virus-like particles have been developed. Two first-generation, U.S. Food and Drug Administration (FDA)-approved vaccines prevent infections and disease caused by HPV16 and HPV18, the two HPV genotypes that cause approximately 70% of cervical cancer, and one of these vaccines also prevents HPV6 and HPV11, the two HPV genotypes that cause 90% of genital warts. A next-generation vaccine, recently approved by the U.S. FDA, targets HPV16, HPV18, and five additional HPV genotypes that together causes approximately 90% of cervical cancer as well as HPV6 and HPV11. In clinical trials, these vaccines have shown high levels of efficacy against disease and infections caused by the targeted HPV genotypes in adolescent females and males and older females. Data indicate population effectiveness, and therefore cost effectiveness, is highest in HPV-naive young females prior to becoming sexually active. Countries that implemented HPV vaccination before 2010 have already experienced decreases in population prevalence of targeted HPV genotypes and related anogenital diseases in women and via herd protection in heterosexual men. Importantly, after more than 100 million doses given worldwide, HPV vaccination has demonstrated an excellent safety profile. With demonstrated efficacy, cost-effectiveness, and safety, universal HPV vaccination of all young, adolescent women, and with available resources at least high-risk groups of men, should be a global health priority. Failure to do so will result in millions of women dying from avertable cervical cancers, especially in low- and middle-income countries, and many thousands of women and men dying from other HPV-related cancers.

show abstract

Section: Immunosuppressed Populationsmentioning

confidence: 99%

Section: First Generation Of Hpv Vaccines: Bi- and Quadrivalentmentioning

confidence: 99%

Prophylactic HPV vaccination: past, present, and future

Castle

Maza²

2015

Epidemiol. Infect.

156

114

View full text Add to dashboard Cite

show abstract

“…Vaccination against HBV remains the mainstay of preventing HBV acquisition both in HIV-infected and uninfected individuals. However, owing to the effect of HIV on the immune system, mounting and maintaining a protective immune response against HBV is sometimes unattainable, with success rates between 18% and 71% [8][9][10].…”

mentioning

confidence: 99%

Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The increase of M-MDSCs is known to be associated with the suppression of T cell functions (Tacke et al, 2012; Cai et al, 2013). As chronically HCV-infected patients, further to have an impaired HCV-specific immunity, are also characterized by reduced responses to heterologous infections (Moorman et al, 2011), extrahepatic tumors (Pol et al, 2018) and vaccines (Buxton and Kim, 2008), we determined the effects of HCV infection and DAA treatments on the whole T cell compartment. To this aim we analyzed the frequencies of different T lymphocyte subsets without considering epitope-specific immune responses.…”

Section: Resultsmentioning

confidence: 99%

“…Within this frame, a hallmark feature of persistent HCV infection is chronic immune activation and dysfunction of several types of immune cells, including naïve and memory CD4 + and CD8 + T cells, which have been linked to perturbation of anti-viral and anti-tumoral immune responses (Urbani et al, 2006; Alanio et al, 2015). These immune alterations may increase susceptibility of chronically infected patients to heterologous infections and their severe consequences (Marrie et al, 2017) and to extra-hepatic tumors (Pol et al, 2018) as well as may decrease responses to vaccination (Buxton and Kim, 2008). At present, it is unclear whether effective inhibition of HCV replication by DAAs influences immune activation and restores the immune functions and immune surveillance capacity in HCV-cured patients (Tumino et al, 2017; Guarino et al, 2018; Singh et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment

Telatin

Nicoli

Frasson

et al. 2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Chronic HCV infection is characterized by several immunological alterations, such as the accumulation of suppressor cells and of hyperactivated T lymphocytes. However, it is unclear whether direct-acting antiviral (DAA)-mediated HCV clearance restores immune dysfunctions. We performed a phenotypic characterization by flow cytometry of different immune cell subsets, including monocytic myeloid-derived suppressor cells (M-MDSCs) and T lymphocytes in 168 patients with persistent HCV infection not treated, under DAA therapies and sustained virological responders. Chronic HCV infection prompted the accumulation of M-MDSCs independently of patient and clinical characteristics, and altered their metabolic properties. HCV RNA was undetectable in the majority of patients just after few weeks of DAA therapy, whereas M-MDSC levels normalized only 6 months after therapy. In addition, HCV infection deeply perturbed the T cell compartment since a re-distribution of memory CD4 + and CD8 + T cells was observed at the expenses of naïve cells, and memory T lymphocytes displayed increased activation. Notably, these features were only partially restored by DAA therapies in the CD4, but not in the CD8, compartment as high immune activation levels persisted in the terminally differentiated memory CD8 + T cells even more than 1 year after sustained virological response. Together, these results suggest that successful DAA therapies do not lead to full immunological reconstitution as fast as viral clearance.

show abstract

Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection

Cited by 6 publications

References 49 publications

Prophylactic HPV vaccination: past, present, and future

Prophylactic HPV vaccination: past, present, and future

Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis

In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment

Contact Info

Product

Resources

About